09/11/2023
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
09/06/2023
Eledon Pharmaceuticals Announces Publication of Data Showing Treatment with Tegoprubart Promotes Kidney and Islet Allograft Survival and Function in Nonhuman Primates
09/05/2023
Eledon Pharmaceuticals Announces First Participant Dosed in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Rejection in Kidney Transplantation
08/16/2023
Eledon Pharmaceuticals Announces Dosing of 10th Patient in Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation
08/10/2023
Eledon Pharmaceuticals Reports Second Quarter 2023 Operating and Financial Results
06/02/2023
Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference
05/11/2023
Eledon Pharmaceuticals Reports First Quarter 2023 Operating and Financial Results
05/04/2023
Eledon Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
05/01/2023
Eledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
03/31/2023
Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
Displaying 11 - 20 of 26